Pernix Therapeutics Holdings (NASDAQ:PTX), According to the latest information the short interest in Pernix Therapeutics Holdings, Inc. plummeted by 7.6% or 660,198 shares. The final shorts are 16.4% of the total floated shares. The positions dropped from 8,738,958 shares on May 31,2016 to 8,078,760 on June 15,2016. According to the per-day average trading of 6,363,765 shares, the days to cover are 1. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Pernix Therapeutics Holdings (NASDAQ:PTX): The stock opened at $0.47 on Friday but the bulls could not build on the opening and the stock topped out at $0.50 for the day. The stock traded down to $0.46 during the day, due to lack of any buying support eventually closed down at $0.47 with a loss of -6.64% for the day. The stock had closed at $0.51 on the previous day. The total traded volume was 7,217,290 shares.
The company shares have dropped -91.73% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $6.44 and the one year low was seen on May 24, 2016. The 50-Day Moving Average price is $0.48 and the 200 Day Moving Average price is recorded at $1.50.
Pernix Therapeutics Holdings (NASDAQ:PTX) has tumbled 3.89% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 8.03% in the last four weeks. The stocks have underperformed the S&P 500 by 2.29% during the past week but Pernix Therapeutics Holdings (NASDAQ:PTX) it has outperformed the index in 4 weeks by 11.3%.
Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).